Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Prognostic value of primary tumor sidedness in patients with non-metastatic IBD related CRC - Is it the exception to the rule? Surgical oncology Kamphues, C., Lefevre, J. H., Wang, J., Amini, N., Beaugerie, L., Kuehn, F., Park, S. H., Andreatos, N., Lauscher, J. C., Enea, D., Lehmann, K. S., Peru, N., Weixler, B., Kirchgesner, J., Degro, C. E., Pozios, I., van Beekum, C. J., Scholch, S., Zambonin, D., Schineis, C., Loch, F. N., Geka, D., Theoxari, M., Wu, B., Wang, P., Antoniou, E., Pikoulis, E., Moussata, D., Theodoropoulos, G., Ouaissi, M., Seeliger, H., Inaba, Y., Scaringi, S., ReiSSfelder, C., Vilz, T. O., Lin, C., Yang, S., Beyer, K., Renz, B. W., Sasaki, K., Margonis, G. A., Svrcek, M., Kreis, M. E. 2022; 45: 101874

Abstract

BACKGROUND: Although primary tumor sidedness (PTS) has a known prognostic role in sporadic colorectal cancer (CRC), its role in Inflammatory Bowel Disease related CRC (IBD-CRC) is largely unknown. Thus, we aimed to evaluate the prognostic role of PTS in patients with IBD-CRC.METHODS: All eligible patients with surgically treated, non-metastatic IBD-CRC were retrospectively identified from institutional databases at ten European and Asian academic centers. Long term endpoints included recurrence-free (RFS) and overall survival (OS). Multivariable Cox proportional hazard regression as well as propensity score analyses were performed to evaluate whether PTS was significantly associated with RFS and OS.RESULTS: A total of 213 patients were included in the analysis, of which 32.4% had right-sided (RS) tumors and 67.6% had left-sided (LS) tumors. PTS was not associated with OS and RFS even on univariable analysis (5-year OS for RS vs LS tumors was 68.0% vs 77.3%, respectively, p=0.31; 5-year RFS for RS vs LS tumors was 62.8% vs 65.4%, respectively, p=0.51). Similarly, PTS was not associated with OS and RFS on propensity score matched analysis (5-year OS for RS vs LS tumors was 82.9% vs 91.3%, p=0.79; 5-year RFS for RS vs LS tumors was 85.1% vs 81.5%, p=0.69). These results were maintained when OS and RFS were calculated in patients with RS vs LS tumors after excluding patients with rectal tumors (5-year OS for RS vs LS tumors was 68.0% vs 77.2%, respectively, p=0.38; 5-year RFS for RS vs LS tumors was 62.8% vs 59.2%, respectively, p=0.98).CONCLUSIONS: In contrast to sporadic CRC, PTS does not appear to have a prognostic role in IBD-CRC.

View details for DOI 10.1016/j.suronc.2022.101874

View details for PubMedID 36257179